Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021320 | 0.85 | CYP3A4 (0.71) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL2016413 | 0.83 | CYP3A4 (0.73) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL10137683 | 0.77 | GPR119 (1.00) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL10137715 | 0.77 | GPR119 (0.83) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL2021706 | 0.76 | GPR119 (0.66) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL9943531 | 0.76 | GPR119 (0.56) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL12574269 | 0.76 | GPR119 (0.65) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL12574266 | 0.74 | GPR119 (0.62) | GPR119CYP3A4 | |
| SCHEMBL9972349 | 0.73 | CYP3A4 (0.61) | GPR119CYP3A4 | |
| SCHEMBL10060479 | 0.73 | GPR119 (1.00) | GPR119CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | claimed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, GCKR, GID4 | GPR119 1/4885CYP3A4 789/4885CYP2C9 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.